Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

计划入组 148 人 · 首次发布于 2025 年 1 月 27 日

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

计划入组 148 人 · 首次发布于 2025 年 1 月 27 日

GP Extended Action Triptorelin

计划入组 27 人 · 首次发布于 2012 年 8 月 28 日

Triptorelin(Decapeptyl, Trelstar, Triptodur)

C₆₄H₈₂N₁₈O₁₃ · Rx

EMAVUSERTIB MESYLATE

Triptorelin patch(Pantec Biosolutions AG)

FERRING SAS

France

Zhejiang Haisen Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceutical Co., Ltd.

China

Foresee Pharmaceuticals to Present Phase 3 KATANA Studies of Novel Prostate Cancer Treatment at ASCO-GU 2025

Debiopharm Completes Enrollment for First-Ever Yearly Injectable Triptorelin Formulation in Pediatric Central Precocious Puberty Trial

Foresee Pharmaceuticals Seeks FDA Approval for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer